Autosomal Dominant Polycystic Kidney Disease Market Report 2034 | Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuti

DelveInsight's "Autosomal Dominant Polycystic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Autosomal Dominant Polycystic Kidney Disease, historical and forecasted epidemiology as well as the Autosomal Dominant Polycystic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Autosomal Dominant Polycystic Kidney Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Autosomal Dominant Polycystic Kidney Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Autosomal Dominant Polycystic Kidney Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Autosomal Dominant Polycystic Kidney Disease market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the autosomal dominant polycystic kidney disease market report:

The market for Autosomal Dominant Polycystic Kidney Disease (ADPKD) is poised for growth as awareness of the condition rises and more effective treatments are developed.
The increasing number of diagnosed ADPKD cases, bolstered by technological advancements that enable earlier detection, creates an ideal environment for the introduction of innovative therapies. Additionally, ongoing research into the genetic basis of ADPKD, along with improvements in non-invasive monitoring and prognostic tools, enhances disease management. Pre-symptomatic diagnosis further opens up opportunities for optimizing patient care.
With only a limited number of FDA-approved therapies available in the U.S., there is significant potential for key players to develop disease-modifying treatments that target the underlying causes of cyst formation and kidney damage in ADPKD.
ADPKD profoundly impacts patients' quality of life, leading to chronic pain, kidney dysfunction, and associated health complications. This highlights the urgent need to address both the physical symptoms and the psychological effects of living with a chronic, progressive disease.

Autosomal Dominant Polycystic Kidney Disease Overview

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. It can lead to kidney enlargement and eventual loss of kidney function, along with other complications affecting various organs.

Causes
ADPKD is primarily caused by mutations in one of two genes:

PKD1 (located on chromosome 16): Mutations here are responsible for the more severe form of the disease, leading to earlier onset and more aggressive symptoms.
PKD2 (located on chromosome 4): Mutations in this gene typically result in a milder form, with symptoms appearing later in life.
The disease follows an autosomal dominant inheritance pattern, meaning that only one copy of the mutated gene from an affected parent can cause the disease in offspring.

Signs and Symptoms
Symptoms often develop in adulthood and may include:

High blood pressure: Common and can be challenging to manage.
Kidney pain: Discomfort in the back or sides due to cyst enlargement.
Hematuria: Blood in the urine, often a result of cyst rupture.
Urinary tract infections: Increased risk due to structural changes in the kidneys.
Kidney stones: Can occur due to altered kidney function.
Progressive renal failure: Leading to end-stage renal disease in some patients.
Extra-renal manifestations: Such as liver cysts, pancreatic cysts, hernias, and cardiovascular issues.
Diagnosis
ADPKD is diagnosed through:

Family history: A detailed history can help identify inherited patterns.
Imaging studies:
Ultrasound: Commonly used for initial evaluation.
CT scan or MRI: Provides a more detailed view of kidney cysts and complications.
Genetic testing: Can confirm mutations in PKD1 or PKD2, especially in ambiguous cases or for family planning.
Treatment Options
While there is no cure for ADPKD, treatment focuses on managing symptoms and slowing disease progression:

Blood pressure management: Often using ACE inhibitors or angiotensin II receptor blockers.
Pain management: Analgesics for kidney pain.
Lifestyle modifications: Diet changes, increased hydration, and regular exercise.
Treating urinary tract infections: Antibiotics as needed.
Kidney function monitoring: Regular check-ups to monitor kidney function and manage complications.
Dialysis or kidney transplantation: In cases of end-stage renal disease, these are necessary for survival.
Conclusion
ADPKD is a significant genetic condition with a range of impacts on kidney health and overall well-being. Early diagnosis and proactive management are key to improving quality of life for those affected. Regular follow-up with healthcare providers is essential to monitor kidney function and address complications as they arise.

Learn more about Autosomal Dominant Polycystic Kidney Disease, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autosomal Dominant Polycystic Kidney Disease Market

The Autosomal Dominant Polycystic Kidney Disease (ADPKD) market in the seven major markets was valued at USD 1,077 million in 2021, with significant growth expected by 2034 during the forecast period from 2022 to 2034.

The market outlook provided in this report offers a comprehensive understanding of historical, current, and projected trends in the ADPKD market. It analyzes the impact of existing therapies, identifies unmet needs, and explores the drivers, barriers, and demand for improved technologies.

Tolvaptan (Jynarque/Jinarc/Samsca), developed by Otsuka Pharmaceuticals, is currently the only approved treatment worldwide specifically for adults with ADPKD. This medication is designed for those at risk of rapid disease progression, functioning by blocking vasopressin receptors in the kidneys to reduce adenylate cyclase activity, which helps slow the decline in kidney function.

Additionally, Otsuka has partnered with the Mario Negri Institute for Pharmacological Research in Italy to evaluate the efficacy of combining tolvaptan with octreotide LAR. This combination therapy, which includes a vasopressin antagonist and a somatostatin analog, has been studied in ADPKD patients with normal or hyperfiltration kidney function.

According to DelveInsight, the ADPKD market in the 7MM is projected to undergo significant changes during the study period from 2020 to 2034.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autosomal Dominant Polycystic Kidney Disease Epidemiology

According to DelveInsight analysis, in 2023, the total number of diagnosed cases of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the seven major markets (7MM) was approximately 194,251. This figure is expected to evolve during the forecast period from 2024 to 2034.

In the U.S. alone, there were about 144,697 diagnosed ADPKD cases in 2023, a number anticipated to rise due to the increasing prevalence of kidney disorders linked to obesity and hypertension.

Among the EU4 countries and the UK in 2023, the UK had the highest number of diagnosed ADPKD cases, totaling approximately 68,138, followed by France with around 61,676 cases. In contrast, Italy reported the lowest prevalence, with nearly 16,476 cases.

In the U.S., age-specific diagnosed cases of ADPKD in 2023 were as follows: under 5 years (1,158), 5-14 years (4,052), 15-24 years (9,695), 25-44 years (45,580), 45-64 years (57,300), and 65 years and older (26,914). These numbers are also expected to change by 2034.

Explore more about Autosomal Dominant Polycystic Kidney Disease Epidemiology at: https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autosomal Dominant Polycystic Kidney Disease Marketed Drugs

JYNARQUE/ JINARC/SAMSCA (tolvaptan): Otsuka America Pharmaceutical

Autosomal Dominant Polycystic Kidney Disease Emerging Drugs

RGLS8429: Regulus Therapeutics
XRx-008: Xortx Therapeutics
VX-407: Vertex Pharmaceuticals

Autosomal Dominant Polycystic Kidney Disease Pipeline Development Activities

The Autosomal Dominant Polycystic Kidney Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Autosomal Dominant Polycystic Kidney Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Autosomal Dominant Polycystic Kidney Disease pipeline development activities at: https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autosomal Dominant Polycystic Kidney Disease Therapeutics Assessment

Major pharma companies such as Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others are working proactively in the Autosomal Dominant Polycystic Kidney Disease Therapeutics market to develop novel therapies which will drive the Autosomal Dominant Polycystic Kidney Disease treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autosomal Dominant Polycystic Kidney Disease Report Key Insights

1. Autosomal Dominant Polycystic Kidney Disease Patient Population
2. Autosomal Dominant Polycystic Kidney Disease Market Size and Trends
3. Key Cross Competition in the Autosomal Dominant Polycystic Kidney Disease Market
4. Autosomal Dominant Polycystic Kidney Disease Market Dynamics (Key Drivers and Barriers)
5. Autosomal Dominant Polycystic Kidney Disease Market Opportunities
6. Autosomal Dominant Polycystic Kidney Disease Therapeutic Approaches
7. Autosomal Dominant Polycystic Kidney Disease Pipeline Analysis
8. Autosomal Dominant Polycystic Kidney Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Autosomal Dominant Polycystic Kidney Disease Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Autosomal Dominant Polycystic Kidney Disease Competitive Intelligence Analysis
4. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance
5. Autosomal Dominant Polycystic Kidney Disease Disease Background and Overview
6. Autosomal Dominant Polycystic Kidney Disease Patient Journey
7. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population
8. Autosomal Dominant Polycystic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Autosomal Dominant Polycystic Kidney Disease Unmet Needs
10. Key Endpoints of Autosomal Dominant Polycystic Kidney Disease Treatment
11. Autosomal Dominant Polycystic Kidney Disease Marketed Products
12. Autosomal Dominant Polycystic Kidney Disease Emerging Therapies
13. Autosomal Dominant Polycystic Kidney Disease Seven Major Market Analysis
14. Attribute Analysis
15. Autosomal Dominant Polycystic Kidney Disease Market Outlook (7 major markets)
16. Autosomal Dominant Polycystic Kidney Disease Access and Reimbursement Overview
17. KOL Views on the Autosomal Dominant Polycystic Kidney Disease Market
18. Autosomal Dominant Polycystic Kidney Disease Market Drivers
19. Autosomal Dominant Polycystic Kidney Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Autosomal Dominant Polycystic Kidney Disease Market report here: https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.